A Phase II, Multi-center, Open-label, Single-arm Study of the Efficacy and Safety of Oral LDE225 in Patients With Hh-pathway Activated Relapsed Medulloblastoma

Trial Profile

A Phase II, Multi-center, Open-label, Single-arm Study of the Efficacy and Safety of Oral LDE225 in Patients With Hh-pathway Activated Relapsed Medulloblastoma

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Sonidegib (Primary) ; Temozolomide
  • Indications Medulloblastoma
  • Focus Therapeutic Use
  • Acronyms CLIMB
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 16 May 2017 Status changed from active, no longer recruiting to completed.
    • 25 Jan 2017 This trial has been completed in Italy (End date:2016-10-05) as per European Clinical Trials Database record.
    • 18 Jan 2017 This trial has been completed in Sweden (End date:2016-10-05) as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top